Meeting Ground Theatre Company

Technicolor Creative Studios: Combined General Shareholders’ Meeting held on May 15, 2023

Retrieved on: 
Monday, May 15, 2023
Parc du 26e Centenaire, Bank statement, Meeting Ground Theatre Company, Urban, Commercial code, Chairperson, Euronext Paris, PIMCO, Combined, Angelo Gordon, Annual general meeting, Id Tech 6, Holding company, Management, Security (finance), Life insurance

Combined General Shareholders’ Meeting held on May 15, 2023

Key Points: 
  • Combined General Shareholders’ Meeting held on May 15, 2023
    Paris (France), May 15, 2023 - Technicolor Creative Studios (Euronext Paris: TCHCS) (the "Company") announces that the Combined General Shareholders’ Meeting (the “Meeting”), chaired by Ms. Anne Bouverot, Chairperson of the Board of Directors, was held today at 2pm at the Urban Station-Espace du Centenaire, 189 rue de Bercy, 75012 Paris.
  • The company's shareholders have been strongly mobilized for this Meeting, which gathered a quorum of 81.72 %.
  • The Board of Directors of the Company, which met at the close of this Meeting, sincerely thanks all shareholders for their support.
  • The Board of Directors, which met after the Meeting, appointed Mrs. Cécile Davies as observer representing Pimco.

Ordinary and Extraordinary General Meeting of May 12, 2022

Retrieved on: 
Thursday, April 21, 2022
Nasdaq, Annual general meeting, Combined, Immunotherapy, Meeting Ground Theatre Company, DBV, Patient, Commercial code, ISIN, Mass meeting, Company, Immune system, Skin, The New Zealand Charity and Legal Gazette, Ticker, SEC, General officer, No, CEST, DBV Technologies, Exercise, Investor, Security (finance), Euronext Paris, Euronext

The preparatory documents for the General Meeting listed in article R. 225-73-1 of the French Commercial Code are posted on the Investors & Media section of the Company’s website located at: https://www.dbv-technologies.com/investor-relations/financial--informati...

Key Points: 
  • Ordinary and Extraordinary General Meeting of May 12, 2022
    DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced that it will hold its Ordinary and Extraordinary General Meeting on May 12, 2022, at 8:30 a.m. CEST at the Companys headquarters located at 177-181 Avenue Pierre Brossolette 92120 Montrouge, France.
  • On May 12, 2022, starting at 8:30 a.m. CEST, the General Meeting will be webcast live on the Company's website https://www.dbv-technologies.com/fr/ in the Events and Presentations section.
  • Shareholders will also be able to access a replay of the Meeting on the Company's website for two years following the General Meeting.
  • With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients.

Exela Reminds Stockholders of Upcoming Annual Meeting and Encourages Voting

Retrieved on: 
Wednesday, December 15, 2021
Phrase, Forward-looking statement, Annual general meeting, U.S. Securities and Exchange Commission, Solution, Public sector, Company, Insurance, BPA, Exela Technologies, NUALS Arts and Literary Annual Meet, Private Securities Litigation Reform Act, Social media, Meeting Ground Theatre Company, Industry, Name, Annual report, THE, SEC, Health, Proxy, Security (finance), Risk, Proxy statement, Information management, Meeting, Accounting, Person, Communication, Public relations, Audit, Ownership

This communication may be deemed solicitation material in respect of the Meeting of the Company.

Key Points: 
  • This communication may be deemed solicitation material in respect of the Meeting of the Company.
  • In connection with the Annual Meeting, the Company has filed with the Securities and Exchange Commission (the SEC) and has mailed or otherwise provided to its stockholders a proxy statement regarding the business to be conducted at the Annual Meeting.
  • The Company may also file other documents with the SEC regarding the business to be conducted at the Annual Meeting.
  • These statements are based on the current expectations of Exela management and are not predictions of actual performance.